The Financial Times, in association with McKinsey & Company, are holding their annual beanfeast: FT Global Pharmaceuticals & Biotechnology Conference, on the 18 & 19 September 2006, at The Dorchester in London.
This year's theme is entitled 'A New Hope?' and questions whether Big Pharma has finally turned a corner.
Sure they have, unfortunately it's a blind downhill bend leading to a dead end!
Topics of discussion will include; 'The Future of Medicine and the Big Pharma Business Model', 'Investing in Biotech', 'The Evolution of Government Healthcare' and 'Investing in R&D - is it time to change the model?'
More programme information can be found on:
http://www.ftconferences.co.uk/pharmabiotech/mppm1.asp
The conference will feature over 40 liggers...... sorry: key and senior-level speakers including;
Mr Alain Aragues, President, Cephalon Europe
Dr Kazem Behbehani, Envoy, World Health Organisation
Dr Joseph M Feczko, Chief Medical Officer, Pfizer Inc
Professor Sir Charles George, Chair, Board of Science, British Medical Association
Mr Hans Peter Hasler, SVP, Head of International, Biogen Idec
Mr Rolf Hoffmann, SVP, Head of European Operations, Amgen
Dr Melanie Lee, Executive Vice President R&D, UCB
Dr John Patterson, Executive Director Development, AstraZeneca Pharmaceuticals
Dr Brian Tempest, Chief Mentor & Executive Vice Chairman of the Board, Ranbaxy
Dr Jean-Luc Vanderheyden, Global Molecular Imaging Leader, Technology and Medical Office, GE Healthcare
Dr Mark Walport, Director, Wellcome Trust
Dr Frank S Walsh, EVP, Discovery, Wyeth Research
Mr Andrew Witty, President, Pharmaceuticals Europe, GlaxoSmithKline
Insider is looking forward to it (they do treat one so well at The Dorchester!).
No comments:
Post a Comment